These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 36481435)
61. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation. Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022 [TBL] [Abstract][Full Text] [Related]
62. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC Front Neurol; 2020; 11():574. PubMed ID: 32754109 [No Abstract] [Full Text] [Related]
63. Machine learning-based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration. Koga S; Zhou X; Dickson DW Neuropathol Appl Neurobiol; 2021 Dec; 47(7):931-941. PubMed ID: 33763863 [TBL] [Abstract][Full Text] [Related]
65. Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings. Mena AM; Chen R; Graff-Guerrero A; Martin SL; Uribe C; Strafella AP Mov Disord Clin Pract; 2023 Dec; 10(12):1725-1737. PubMed ID: 38094644 [TBL] [Abstract][Full Text] [Related]
67. Elevated Serum SIRT 2 May Differentiate Parkinson's Disease From Atypical Parkinsonian Syndromes. Singh AP; Ramana G; Bajaj T; Singh V; Dwivedi S; Behari M; Dey AB; Dey S Front Mol Neurosci; 2019; 12():129. PubMed ID: 31244600 [TBL] [Abstract][Full Text] [Related]
68. New advances in tau imaging in parkinsonism. Valli M; Strafella AP Int Rev Psychiatry; 2017 Dec; 29(6):628-635. PubMed ID: 29206491 [TBL] [Abstract][Full Text] [Related]
69. Secondary Protein Aggregates in Neurodegenerative Diseases: Almost the Rule Rather than the Exception. Moda F; Ciullini A; Dellarole IL; Lombardo A; Campanella N; Bufano G; Cazzaniga FA; Giaccone G Front Biosci (Landmark Ed); 2023 Oct; 28(10):255. PubMed ID: 37919089 [TBL] [Abstract][Full Text] [Related]
70. Radiomics on routine T1-weighted MRI can delineate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. Tupe-Waghmare P; Rajan A; Prasad S; Saini J; Pal PK; Ingalhalikar M Eur Radiol; 2021 Nov; 31(11):8218-8227. PubMed ID: 33945022 [TBL] [Abstract][Full Text] [Related]
71. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM; JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011 [TBL] [Abstract][Full Text] [Related]
72. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. Yekhlef F; Ballan G; Macia F; Delmer O; Sourgen C; Tison F J Neural Transm (Vienna); 2003 Feb; 110(2):151-69. PubMed ID: 12589575 [TBL] [Abstract][Full Text] [Related]
73. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Halliday GM; Macdonald V; Henderson JM Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651 [TBL] [Abstract][Full Text] [Related]
74. A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. Xiang C; Cong S; Tan X; Ma S; Liu Y; Wang H; Cong S NPJ Parkinsons Dis; 2022 Nov; 8(1):165. PubMed ID: 36446820 [TBL] [Abstract][Full Text] [Related]
75. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509 [TBL] [Abstract][Full Text] [Related]
77. Phosphorylated α-synuclein in Parkinson's disease. Wang Y; Shi M; Chung KA; Zabetian CP; Leverenz JB; Berg D; Srulijes K; Trojanowski JQ; Lee VM; Siderowf AD; Hurtig H; Litvan I; Schiess MC; Peskind ER; Masuda M; Hasegawa M; Lin X; Pan C; Galasko D; Goldstein DS; Jensen PH; Yang H; Cain KC; Zhang J Sci Transl Med; 2012 Feb; 4(121):121ra20. PubMed ID: 22344688 [TBL] [Abstract][Full Text] [Related]
78. α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson's disease. Cao Z; Wu Y; Liu G; Jiang Y; Wang X; Wang Z; Feng T Neurosci Lett; 2019 Mar; 696():114-120. PubMed ID: 30579996 [TBL] [Abstract][Full Text] [Related]
79. Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work? Del Giudice KP; Cosgaya M; Zaro I; Ravasi V; Santacruz P; Painous C; Fernández M; Cámara A; Compta Y Parkinsonism Relat Disord; 2024 May; 122():106080. PubMed ID: 38508903 [TBL] [Abstract][Full Text] [Related]
80. microRNA and circRNA in Parkinson's Disease and atypical parkinsonian syndromes. Bougea A; Stefanis L Adv Clin Chem; 2023; 115():83-133. PubMed ID: 37673523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]